OSLI Retina

February 2021

Issue link: http://osliretina.healio.com/i/1340056

Contents of this Issue


Page 60 of 63

111 © Ophthalmic Surgery, Lasers & Imaging Retina News and Notes Faricimab Meets Primary Endpoints in Phase 3 Wet AMD Studies Faricimab met its primary endpoint in two phase 3 studies, with injections every 16 weeks achieving noninferior visual acuity outcomes compared aflibercept every 8 weeks in wet age-related macular degeneration, according to a press release. In the TENAYA and LUCERNE studies, 45% of participants were dosed with faricimab (Genentech, South San Francisco, CA) every 16 weeks in the first year. Subjects achieved noninferior visual acuity outcomes compared with patients who received Eylea (aflibercept; Regeneron, Tarrytown, NY) injections every 8 weeks, the release said. In addition, faricimab presented no new or unexpected safety signals. The identical, randomized, multicenter, double-masked, global studies are evalu- ating the efficacy and safety of faricimab in 1,329 subjects with wet AMD. "We have now seen positive and consistent results in four phase 3 studies for faricimab across both neovascular age-related macular degeneration and diabetic macular edema," Levi Garraway, MD, PhD, chief medical officer and head of global product development at Genentech, said in the release. "We look forward to submit- ting these data to global regulatory authorities, with the aim of bringing this promis- ing treatment option to patients as soon as possible." Positive results were reported earlier for the YOSEMITE and RHINE phase 3 stud- ies in diabetic macular edema. Originally published on www.Healio.com on January 25, 2021. Ophthalmic Surgery, Lasers & Imaging Retina® (ISSN-2325-8160, Canadian BN-12978 0466 RT ) is published 12 times per year by SLACK Incorporated, and is the official journal of Retina World Congress. Publication Office: SLACK Incorporated, 6900 Grove Road, Thorofare, NJ 08086-9447. Telephone (856) 848-1000. Printed in the USA. Periodicals Class Postage Paid at Deptford, NJ 08096 and at additional mailing offices. Contents copyrighted by SLACK Incorporated, 2021. All rights reserved. No part of this publication may be reproduced with- out prior written consent of the publisher. All requests to reprint or use material published herein should be directed to the Request Permissions link on every article page at Healio.com/ophthalmology/journals/osli. Subscription rates in the U.S. and possessions: Individuals: One year—print $228, electronic only: $203. Institutional: One year—$719. Residents and fellows: $114 for one year (a letter of certification indicating residency of the subscriber is required). Canada add 5% GST, all other countries add $64 per year. All subscriptions, without exception, will start with the first issue pub- lished after the order is received. Single copies and back issues, when available, are $103. Payment must accompany order. Sub- scription requests should be addressed to the publisher. Change of Address: Notice should be sent to the publisher six weeks in advance of effective date. Include old and new ad- dresses with zip codes. The publisher cannot accept responsibility for undelivered copies. Duplicate copies will not be sent to re- place ones undelivered through failure to notify the publisher of change of address. POSTMASTER: Send Form 3547 to Ophthalmic Surgery, Lasers & Imaging Retina, SLACK Incorporated, 6900 Grove Road, Thorofare, NJ 08086-9447. Articles are intended for informational purposes only and should not be used as the basis of patient treatment. All opinions expressed by authors and quoted sources are their own and do not necessarily reflect the opinions of the editors, publisher, or editorial boards of SLACK Incorporated. The acceptance of advertising in no way implies endorsement by the editors, publisher, or editorial boards of SLACK Incorporated. See website for print and web advertising policy. Readers with queries about the Journal's policies on error correction, version control, journal of record, ancillary material, or archiving should contact osli@healio.com. The Journal staff have no financial relationships to disclose. Financial disclosures for the Editor and members of the Editorial Board are on file with the editorial office. Indexed in: Medline/PubMed, ProQuest, EMCare, EMBASE, Science Citation Index, Current Contents/Clinical Medicine, BioEn- gineering Abstracts, CAB Abstracts, and SCOPUS. Follow OSLIJournal OSLI Retina SLACK Incorporated 6900 Grove Road Thorofare, NJ 08086-9447 Phone: 856-994-9900 Email: osli@healio.com SLACK Incorporated EDITORIAL Senior Vice President Stephanie Arasim Portnoy Vice President, Editorial Jennifer A. Kilpatrick, ELS Director, Electronic Publishing & Production Karen G. Stanwood, ELS Executive Editor Cara Dickinson Peer Review Coordinator Dawn Barber SALES Chief Commercial Officer Matthew J. Holland Group Sales Director, Eye Care Scott Wright Senior Account Manager Kathy Huntley National Account Manager Laura Renna Director, Sales Administration & Support Carolyn Boerner Classified/Recruitment Sales KERH Group LLC slack@kerhgroup.com Reprints/Eprints, Licensing Opportunities Sheridan Content Solutions scsreprints@sheridan.com MARKETING & DESIGN Vice President, Creative Director Thomas Cavallaro Director of Audience Development Stephanie McHugh Production Associate Ryan Davis The Wyanoke Group President Peter N. Slack Chief Operating Officer John C. Carter Chief Financial Officer Darrell Blood Chief Technology Officer Linda Baker Senior Vice President Denise Mealey

Articles in this issue

Links on this page

Archives of this issue

view archives of OSLI Retina - February 2021